Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Investment Securities: 2015-2023

Historic Gains from Investment Securities for Spyre Therapeutics (SYRE) over the last 7 years, with Jun 2023 value amounting to -$923,000.

  • Spyre Therapeutics' Gains from Investment Securities fell 627.43% to -$923,000 in Q2 2023 from the same period last year, while for Jun 2023 it was -$1.7 million, marking a year-over-year decrease of 370.51%. This contributed to the annual value of -$915,000 for FY2023, which is 109.04% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Gains from Investment Securities is -$923,000, which was down 11,637.50% from $8,000 recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Gains from Investment Securities registered a high of $228,000 during Q2 2021, and its lowest value of -$923,000 during Q2 2023.
  • For the 3-year period, Spyre Therapeutics' Gains from Investment Securities averaged around -$83,100, with its median value being $85,500 (2021).
  • As far as peak fluctuations go, Spyre Therapeutics' Gains from Investment Securities skyrocketed by 3,340.00% in 2022, and later tumbled by 627.43% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Gains from Investment Securities (Quarterly) stood at $7,000 in 2019, then declined by 28.57% to $5,000 in 2020, then surged by 3,280.00% to $169,000 in 2021, then tumbled by 594.67% to -$836,000 in 2022, then tumbled by 627.43% to -$923,000 in 2023.
  • Its Gains from Investment Securities was -$923,000 in Q2 2023, compared to $8,000 in Q1 2023 and -$836,000 in Q4 2022.